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Introduction: In malignant pleural mesothelioma, targeting
angiogenesis with cediranib, a vascular endothelial growth
factor receptor and platelet-derived growth factor receptor
inhibitor, may have therapeutic potential.
Methods: S0905 phase I combined cediranib (two dose
cohorts [30 mg and 20 mg daily]) with cisplatin-pemetrexed
for six cycles followed by maintenance cediranib in unre-
sectable chemonaive patients with malignant pleural meso-
thelioma of any histologic subtype. The primary end point
established themaximum tolerated dose in combinationwith
cisplatin-pemetrexed in a dose deescalation scheme.
Results: A total of 20 patients were enrolled (seven to the
30-mg cohort and 13 to the 20-mag cohort). In the cediranib
30-mg cohort, two of the initial six patients reported
dose-limiting toxicities and the dose was deemed too toxic
to continue. In the next cohort, two patients experienced
dose-limiting toxicities, and thus, the maximum tolerated
dose of cediranib was established as 20 mg. During the six
cycles of cisplatin-pemetrexed-cediranib, 20 mg, there were
grade 3 toxicities (neutropenia and gastrointestinal) and
grade 4 thrombocytopenia. No patients had any signiﬁcant
episodes of bleeding. According to the Response Evaluation
Criteria in Solid Tumors (n ¼ 17 evaluable patients), the
median progression-free survival was 12.8 months (95%
conﬁdence interval [CI]: 6.9–17.2); according to the Modi-
ﬁed Response Evaluation Criteria in Solid Tumors (n ¼ 19
evaluable patients), the median progression-free survival
was 8.6 months (95% CI: 6.1–10.9). For all patients, thedisease control rate at 6 weeks was 90% and median
overall survival time was 16.2 months (95% CI: 10.5–28.7).
Conclusions: Cediranib combinedwith cisplatin-pemetrexed
has a reasonable toxicity proﬁle and preliminary promising
efﬁcacy. The phase II S0905 trial will evaluate the efﬁcacy of
the triplet regimen compared with the current standard of
care, cisplatin-pemetrexed.
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Malignant pleural mesothelioma (MPM) is a rare
disease with limited treatment options and a median
survival time of 12 months for unresectable patients.1
In the frontline setting, cisplatin-pemetrexed has been
the accepted standard of care since 2003.1 Recently,
the ﬁrst therapeutic advance since the approval of
pemetrexed and cisplatin was made when the addition of
bevacizumab to the cisplatin-pemetrexed backbone
prolonged survival over cisplatin-pemetrexed alone.2
This success has provided the impetus to continue to
evaluate angiogenesis inhibitors in this disease.
The angiogenic pathway plays an important role in
mesothelioma. Preclinical studies have demonstrated a
high dependency of MPM on the vascular endothelial
growth factor (VEGF)/vascular endothelial growth factor
receptor (VEGFR) and platelet-derived growth factor
(PDGF)/platelet-derived growth factor receptor (PDGFR)
pathway.3–5 Mesothelioma tumor cells have the highest
secretion of VEGF ligand with pathway activation
compared to other solid tumors and rely on the PDGF/
PDGFR pathway for an autocrine loop proliferation.3,6–13
In vitro and xenograft mesothelioma studies14–16 have
demonstrated that inhibition of the PDGF pathway leads
to antitumor effects, and a phase I trial17 of imatinib
mesylate, a PDGFR inhibitor, combined with cisplatin-
pemetrexed showed potential clinical beneﬁt but low
tolerance to therapy.
Previously, three small phase II trials18–20 found that
the addition of bevacizumab to platinum doublets in
mesothelioma did not appear to augment clinical efﬁcacy
in the intent-to-treat population. In one of these studies,18
patients with levels of serum VEGF higher than the
median had a worse progression-free survival (PFS) and
overall survival (OS), and they had less survival beneﬁt
with the addition of bevacizumab. As bevacizumab targets
VEGF, an intrinsic mechanism of resistance may be
present in mesothelioma that secretes high levels of
VEGF. However, the French Intergroupe Francophone de
Cancerologie Thoracique recently conducted the phase II/
III Mesothelioma Avastin Cisplatin Pemetrexed Study
(MAPS) trial2 in 448 patients and demonstrated a greater
than 2-month median OS beneﬁt with the addition of
bevacizumab to cisplatin-pemetrexed in the intent-to-treat
population. This study supports the hypothesis that
antiangiogenic agents have clinical efﬁcacy in certain
patients with mesothelioma.
We hypothesized that targeting the VEGF receptor
would potentially bypass the potential resistance of high
VEGF ligand secretion and ultimately provide clinical
efﬁcacy for patients with mesothelioma. In addition,
targeting other angiogenic pathways, such as PDGF/
PDGFR, made sense to enhance the antitumor effect.21Cediranib (Recentin, AZD2171 [AstraZeneca Phar-
maceuticals, Cheshire, United Kingdom]) is an oral
tyrosine kinase inhibitor (TKI) of VEGFR1,2,3, PDGFR, and
c-KIT. Cediranib at a daily dose of 45 mg demonstrated
antitumor activity in patients with mesothelioma in a
second-line monotherapy trial, SWOG 0509.22 This study
reported a 9% response rate and 34% disease stabili-
zation rate with a median PFS of 2.56 months and
median OS of 9.5 months. Most patients did require a
dose reduction from the daily dose of 45 mg.
A frontline trial, SWOG 0905, was therefore designed
as a phase I/II combination trial of cisplatin-pemetrexed
with and without cediranib. The phase I portion was
designed as a safety study to evaluate two different
doses of cediranib (30 mg and 20 mg) in combination
with cisplatin-pemetrexed for six cycles of therapy
followed by cediranib maintenance therapy. This article
reports on the results of the phase I trial. The phase II
portion of the trial has completed enrollment of 98
patients and data analysis is expected in winter 2017.
Methods
Patients and Methods
Adult patients with a histologically conﬁrmed diag-
nosis of MPM of any histologic subtype were eligible.
Other key inclusion criteria included disease measurable
or not measurable by either Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1 or Modiﬁed
RECIST for Pleural Tumors; no prior systemic therapy
(chemotherapy or other biologic therapy); a Zubrod
performance status of 2 or less; and adequate hepatic
(serum bilirubin level not exceeding the upper limit of
normal and transaminase level of 1.5 the upper limit
of normal), hematologic (absolute neutrophil count of
1500/mL and platelet count of 100,000/mL), renal
(serum creatinine level 1.5 the upper limit of normal
or a measured creatinine clearance of 50 mL/min), and
cardiac function. Patients may have undergone a prior
surgical procedure (e.g., pleurectomy or pleurodesis) or
received prior radiation therapy. Patients were not
eligible if they had severe systemic comorbid disease or
a history of signiﬁcant cardiac disease, uncontrolled
hypertension, signiﬁcant proteinuria, a prolonged QTc
interval, or gastrointestinal tract disease resulting in the
inability to take oral medication. Patients could not have
a history of clinically signiﬁcant hemoptysis or other
bleeding issues.
The protocol and informed consent document were
approved by the Cancer Therapy Evaluation Program of
the National Cancer Institute and the institutional review
boards of the participating SWOG member sites. Written
informed consent was obtained from all patients before
enrollment. This study was monitored by the Data and
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tient consent was required for the banking and future
use of specimens.
Patient history taking, physical examination, and
hematologic and chemical laboratory analyses were
performed before cycle 1 and each subsequent cycle
of therapy. Radiographic tumor measurements were
performed after every two treatment cycles. Tumor
response assessments were determined by RECIST 1.1.
However, additional tumor measurements using the
Modiﬁed RECIST measurement system as described in
Tsao et al.23 were also obtained for exploratory research
purposes. Patients were withdrawn from the study in the
event of disease progression or symptomatic deteriora-
tion, unacceptable toxicity as assessed by the study
physician, treatment delay of greater than 3 weeks, need
for more than the allowed number of dose modiﬁcations,
or patient request.
Cisplatin (75 mg/m2) and pemetrexed (500 mg/m2)
were administered intravenously on day 1 every 3
weeks. Dose modiﬁcations for chemotherapy were con-
ducted per standard guidelines. Vitamin supplementa-
tion with folic acid, 400 mg daily, and vitamin B12, 1000
mg by intramuscular injection every 9 weeks, was
mandatory for all patients and initiated 1 week (on
day –7) before cycle 1 of cisplatin-pemetrexed and
cediranib. Carboplatin substitution was allowed if
toxicity to cisplatin developed. Cediranib was given
concomitantly on day 1 and continued daily. Two doses
of cediranib, 30 mg and 20 mg, were evaluated. No
further dose reductions or modiﬁcations were allowed.
No primary prophylaxis with granulocyte colony-
stimulating factor or antibiotics was allowed.
Statistics
The primary end point of this study was to establish
the maximum tolerated dose (MTD) and the recom-
mended phase II dose of cediranib in combination with
cisplatin and pemetrexed in patients with MPM. The
phase I trial was a limited dose deescalation study with
two potential doses of cediranib (30 mg and 20 mg
daily). The dose-limiting toxicities (DLTs) were deﬁned
as febrile neutropenia, grade 4 neutropenia of more than
7 days’ duration, grade 4 thrombocytopenia, or grade 3
or 4 nonhematologic toxicity (excluding alopecia). Only
DLTs occurring during cycle 1 were used to guide dosing
determination. Patients were considered evaluable for
DLT if they received at least 14 doses (50% of the
planned dose) of cediranib in combination with peme-
trexed and cisplatin during cycle 1. Patients who were
not evaluable for DLT were replaced. The regimen was
considered safe and the MTD determined if the DLT rate
of cediranib and cisplatin-pemetrexed was 33% or
lower.The following dosing scheme was used. Enroll six
evaluable patients at the 30-mg dose level. If three or
more patients experienced a DLT, enrollment would stop
and the study would proceed to the 20-mg dose level. If
zero to two patients experienced a DLT, four additional
patients were accrued. If zero to three patients experi-
enced a DLT, then the 30-mg dose would be declared the
MTD. If four or more patients experienced a DLT,
the trial would continue to the 20-mg dose level. At the
reduced dose level the aforesaid rules would apply. If
zero to three of 10 patients experienced a DLT, the
20-mg dose level would be the MTD. However, if three of
the initial six or four or more out of 10 patients expe-
rienced a DLT, then neither the 30- mg nor the 20-mg
would be considered the MTD.
Only patients with measurable disease at baseline,
as deﬁned by the speciﬁc criteria, were included in the
response analysis. PFS, disease control rate, and
duration of response were also analyzed by RECIST 1.1
and by Modiﬁed RECIST. Disease control was deﬁned
as absence of progression at the ﬁrst follow-up
assessment. Duration of response was deﬁned as time
from the date of initial documentation of partial or
complete response until date of progression or death,
with patients censored at date of last contact if last
known to be alive and progression-free. OS, PFS, and
duration of response were all estimated by the method
of Kaplan-Meier.
Results
A total of 20 patients were enrolled into this
study from March 15, 2010, until July 18, 2011. Patient
demographics are listed in Table 1. There were seven
patients in dose cohort 1 (30 mg) and 13 patients in dose
cohort 2 (20 mg). Both cohorts were similar, with a
median age of 64 years, predominantly white ethnicity
(71% and 77%), and majority performance status of 0 or
1 (100% and 92%). However, whereas all patients
enrolled in the 30-mg cohort had the epithelioid histo-
logic subtype, the 20-mg cohort included two patients
with the biphasic histologic subtype of mesothelioma
and one with a not otherwise speciﬁed histologic
subtype.
In the cediranib 30-mg dose cohort, one patient, who
misunderstood instructions, took only four doses of
cediranib during cycle 1 and was thus not evaluable for
DLT. This patient was replaced per protocol. Two of the
initial six evaluable patients reported DLTs and were
dose-reduced—one on account of grade 3 fatigue and
one owing to grade 3 fatigue and grade 3 diarrhea.
Although technically this did not reach the formal stop-
ping rule (three or more of the ﬁrst six patients with
a DLT), the Lung Committee leadership and treating
investigators decided that the cediranib dose of 30 mg
Table 1. Patient Demographics
Characteristic
Cohort 1 Cohort 2
Cisplatin-Pemetrexed Cisplatin-Pemetrexed
Cediranib, 30 mg Daily (n ¼ 7) Cediranib, 20 mg Daily (n ¼ 13)
Median age (range), y 64.9 (47.5–83.6) 64.0 (43.7–74.1)
Sex (male-to-female ratio) 5:2 10:3
Race
White 5 (71%) 10 (77%)
African American 1 (14%) 1 (8%)
Asian 1 (14%) 1 (8%)
Unknown 0 (0%) 1 (8%)
Hispanic 0% 1 (8%)
Performance status
0–1 7 (100%) 12 (92%)
2 0 (0%) 1 (8%)
Histologic subtype
Epithelioid 7 (100%) 10 (77%)
Biphasic 0 (0%) 2 (15%)
Sarcomatoid 0 (0%) 0 (0%)
Mesothelioma NOS 0 (0%) 1 (8%)
History of surgical procedure
VATs procedure for pleural biopsy 6 (68%) 7 (54%)
Partial pleurectomy/decortication 0 (0%) 2 (15%)
Pleurectomy/decortication 0 (0%) 0 (0%)
Extrapleural pneumonectomy 0 (0%) 1 (8%)
History of radiotherapy
Deﬁnitive (curative) intent 0 (0%) 1 (8%)
Palliative 3 (43%) 1 (8%)
Measurable disease per RECIST 1.1 7 (100%) 10 (77%)
Measurable disease per Modiﬁed RECIST for Pleural Tumors 7 (100%) 12 (92%)
NOS, not otherwise speciﬁed; VATS, video-assisted thoracoscopic surgery; RECIST, Response Evaluation Criteria in Solid Tumors.
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patients required dose reductions to 20 mg of cediranib
during cycle 1. Therefore, the study was not expanded to
a total of 10 patients.
Six of the seven patients completed the six cycles of
the triplet regimen, and ﬁve had nine or more cycles of
maintenance therapy. The median number of cycles of all
study treatment in the 30-mg cohort was 17 (range two
to 32). The most common toxicities associated with
therapy during cycle 1 in the 30-mg cediranib cohort
included grade 2 or 3 fatigue, grade 1 or 2 nausea, and
grade 1 or 2 lymphopenia, (Table 2). When all six cycles
of therapy for the combination of cisplatin-pemetrexed
in the 30-mg cediranib cohort were assessed (Table 3),
ﬁve patients (71%) had grade 3 adverse events due to
diarrhea (n ¼ 1), fatigue (n ¼ 2), lymphopenia (n ¼ 2),
and neutropenia (n ¼ 1). The most common grade 1 or 2
toxicities during all six cycles of triplet therapy included
gastrointestinal complaints (anorexia, diarrhea, nausea,
and vomiting), fatigue, hypomagnesemia, hyponatremia,
lymphopenia, neutropenia, and anemia. There were
three reported cases of grade 1 or 2 hypertension. Five
of the seven patients (71%) had chemotherapy delaysand three patients required reductions of their cediranib
dose, with one patient also requiring a dose delay of
cediranib (Supplementary Tables 1 and 2).
In the maintenance cediranib 30-mg portion (n ¼ 5
evaluable patients), the most common toxicities reported
were diarrhea, hypomagnesemia, lymphopenia, neu-
tropenia, nausea, vomiting, and proteinuria. There were
ﬁve grade 3 events of diarrhea, hand-foot syndrome,
hypomagnesemia, neutropenia, and weight loss (one
each). Two of the ﬁve patients who received mainte-
nance cediranib at a dose of 30 mg required dose delays
(see Supplementary Table 1).
Thirteen patients were accrued to the lower dose
level of cisplatin-pemetrexed and cediranib, 20 mg daily.
One patient received only 13 daily doses of cediranib
during cycle 1 because of a drug shipment error and was
not evaluable for DLT. This patient was replaced per
protocol. In addition, two patients who were in screening
at the time of accrual completion were allowed to
enroll. During cycle 1, two patients experienced DLTs,
one due to grade 3 dehydration and one due to grade 3
hyponatremia. Thus, 20 mg of cediranib was determined
to be the MTD.
Table 2. Number of Patients with Treatment-Related Adverse Events That Occurred during Cycle 1 among Patients Evaluable
for Dose-Limiting Toxicities
Adverse Event
Cisplatin-Pemetrexed Cediranib,
30 mg (n ¼ 6)
Cisplatin-Pemetrexed Cediranib,
20 mg (n ¼ 12)
Grade Grade
1–2 3 1–2 3
Nausea 3 0 8 0
Fatigue 3 2 5 0
Anorexia 2 0 4 0
Diarrhea 0 1 4 0
Hypomagnesemia 1 0 4 0
Hoarseness 2 0 2 0
Vomiting 2 0 2 0
Lymphopenia 4 0 0 0
Leucopenia 2 0 1 1
Abdominal pain 1 0 2 0
Constipation 2 0 1 0
Dehydration 0 0 2 1
Neutropenia 1 0 2 0
Anemia 1 0 1 0
BIlirubinemia 0 0 2 0
Edema, limbs 1 0 1 0
Hypertension 1 0 1 0
Hyponatremia 0 0 1 1
Mucositis, oral 1 0 0 1
Weight loss 0 0 2 0
Maximum grade of any adverse event 4 2 9 3
Note: Events less than grade 3 experienced by only one patient have been omitted.
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regimen. The median number of cycles of all study treat-
ment received was 11 (range one to 41). During the triplet
regimen, six of 20 patients (46%) required a chemotherapy
delay and one patient also required a dose reduction of
cisplatin (see Supplementary Table 1). Three patients
required discontinuation of cisplatin-pemetrexed treat-
ment, including two patients who were removed from all
protocol treatment owing to toxicity. The most common
toxicities during cycle 1were grade 1 or 2 anorexia, grade 1
or 2 diarrhea, grade 1 or 2 fatigue, grade 1 hypomagnese-
mia, and grade 1 or 2 nausea (see Table 2). For all six cycles
of combination cisplatin-pemetrexedwith cediranib, 20mg
(seeTable 3), themost common toxicitieswere grade1 or2
gastrointestinal symptoms (anorexia, nausea, vomiting,
and diarrhea), dehydration, fatigue, hypomagnesemia,
hyponatremia, hypokalemia, anemia, neutropenia, and
proteinuria. Grade 3 toxicities were reported with neu-
tropenia (n ¼ 3), vomiting (n ¼ 2), and one event each
of abdominal pain, anemia, constipation, dehydration,
diarrhea, fatigue, hypertension, hyponatremia, hypomag-
nesemia, mucositis, nausea, neuropathy, and pulmonary
hypertension.
Two episodes of grade 4 thrombocytopenia were also
reported. There were no patients with any signiﬁcantepisodes of bleeding. One patient in the cediranib 20-mg
cohort was switched to carboplatin during cycle 4 on
account of grade 3 neuropathy. One treatment-related
death was noted in a patient who completed three
cycles the triplet therapy and was suspected to have a
septic event from pneumonia with associated hypoten-
sion and delirium.
Ten patients proceeded to maintenance therapy
with cediranib. In the maintenance phase, the cediranib
20-mg cohort had grade 3 events of abdominal pain
(n ¼ 1), diarrhea (n ¼ 1), heart failure (n ¼ 1), and
dyspnea (n ¼ 2). Three patients required dose delays
and one patient required a dose reduction (see
Table 4).
Efﬁcacy
The median follow-up among the four patients still
alive as of last contact was 26 months (range 9–56).
Table 5 summarizes the efﬁcacy results. Two separate
radiographic response measurements were utilized,
RECIST 1.1 and Modiﬁed RECIST. In the 30-mg cohort,
two out of seven evaluable patients had a partial
response by RECIST 1.1, for a response rate of 29%
(95% conﬁdence interval [CI]: 0%–62%). The duration
of these responses were 7.2 and 25.3 months. When
Table 3. Number of Patients with Treatment-Related Adverse Events during Cycles 1 to 6 of Cisplatin-Pemetrexed-Cediranib
Adverse Event
Cisplatin-Pemetrexed Cediranib,
30 mg (n ¼ 7)
Cisplatin-Pemetrexed Cediranib,
20 mg (n ¼ 13)
Grade Grade
1–2 3 4 5 1–2 3 4 5
Nausea 5 0 0 0 11 1 0 0
Hypomagnesemia 6 0 0 0 9 0 0 0
Fatigue 4 2 0 0 6 1 0 0
Neutropenia 3 1 0 0 6 2 0 0
Vomiting 4 0 0 0 6 2 0 0
Anemia 4 0 0 0 7 1 0 0
Diarrhea 3 1 0 0 6 1 0 0
Leucopenia 6 0 0 0 4 1 0 0
Anorexia 5 0 0 0 6 0 0 0
Hyponatremia 4 0 0 0 4 1 0 0
Proteinuria 2 0 0 0 6 0 0 0
Thrombocytopenia 3 0 0 0 1 1 2 0
Dehydration 2 0 0 0 2 3 0 0
Weight loss 3 0 0 0 4 0 0 0
Constipation 3 0 0 0 2 1 0 0
Hypertension 3 0 0 0 2 1 0 0
Lymphopenia 3 2 0 0 0 0 0 0
Abdominal pain 2 0 0 0 2 1 0 0
Hoarseness 3 0 0 0 2 0 0 0
Hypoalbuminemia 3 0 0 0 2 0 0 0
Hypokalemia 0 0 0 0 3 1 0 0
AST level increased 3 0 0 0 1 0 0 0
Hypocalcemia 2 0 0 0 2 0 0 0
Mucositis oral 2 0 0 0 0 1 0 0
ALT level increased 2 0 0 0 1 0 0 0
Edema, limbs 2 0 0 0 1 0 0 0
Headache 1 0 0 0 2 0 0 0
Pain 2 0 0 0 1 0 0 0
Dyspnea 1 0 0 0 0 1 0 0
Peripheral sensory neuropathy 0 0 0 0 1 1 0 0
Alkaline phosphatase level increased 1 0 0 0 1 0 0 0
Arthralgia 2 0 0 0 0 0 0 0
Bilirubinemia 0 0 0 0 2 0 0 0
Creatinine level increased 1 0 0 0 1 0 0 0
Dizziness 0 0 0 0 2 0 0 0
Decreased oral intake 1 0 0 0 1 0 0 0
Generalized muscle weakness 0 0 0 0 2 0 0 0
Hyperkalemia 0 0 0 0 2 0 0 0
Hyperuricemia 0 0 0 0 2 0 0 0
Hypothyroidism 1 0 0 0 1 0 0 0
Myalgia 2 0 0 0 0 0 0 0
Altered mental status 0 0 0 0 0 0 0 1
Maximum grade of any adverse event 3 4 0 0 4 7 1 1
Note: Events less than grade 3 experienced by only one patient have been omitted.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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with a partial response, including one that was uncon-
ﬁrmed, resulting in an estimated response rate of 71%,
(95% CI: 38%–100%). The median duration of these
responses was 5.9 months (95% CI: 3.0–9.7). The dis-
ease control rate was 86% (95% CI: 60%–100%) with
both criteria.In the 30-mg cohort, the median PFS by RECIST
1.1 was 12.8 months (95% CI: 3.1–14.6) and the me-
dian PFS by Modiﬁed RECIST was 10.1 months (95% CI:
4.5–10.9). The median OS was 16.2 months (95% CI:
7.5–28.7) (Fig. 1).
Within the 20-mg cohort, 10 of 13 patients had
measurable disease. One patient withdrew consent after
Table 4. Number of Patients with Treatment-Related Adverse Events during Maintenance Cediranib Therapy
(Cycle 7 or Later)
Adverse Event
Maintenance Cediranib 30 mg (n ¼ 5) Maintenance Cediranib 20 mg (n ¼ 10)
Grade Grade
1–2 3 1–2 3
Proteinuria 5 0 6 0
Hypomagnesemia 3 1 6 0
Anemia 3 0 7 0
Diarrhea 3 1 3 1
Anorexia 3 0 5 0
Creatinine level increased 1 0 6 0
Nausea 3 0 4 0
Vomiting 4 0 3 0
Leucopenia 5 0 2 0
Neutropenia 2 1 3 0
Weight loss 2 1 3 0
Fatigue 2 0 3 0
Thrombocytopenia 2 0 3 0
Dyspnea 1 0 1 2
Constipation 2 0 2 0
Hypertension 2 0 2 0
Metabolic/nutrition disorders, other 2 0 2 0
Abdominal pain 1 0 1 1
AST level increased 2 0 1 0
Bilirubinemia 1 0 2 0
Hoarseness 2 0 1 0
Hyperkalemia 0 0 3 0
Hyponatremia 2 0 1 0
Lymphopenia 3 0 0 0
Alkaline phosphatase level increased 2 0 0 0
Dysgeusia 1 0 1 0
Hyperglycemia 0 0 2 0
Hypoalbuminemia 1 0 1 0
Hypothyroidism 1 0 1 0
Pain 2 0 0 0
Diverticultis 0 0 0 1
Hand-foot syndrome 0 1 0 0
Heart failure 0 0 0 1
Maximum grade of any adverse event 2 3 6 4
Note: Events less than grade 3 experienced by only one patient have been omitted.
AST, aspartate aminotransferase.
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any follow-up disease assessments on protocol. This
patient was counted in the denominator as a nonre-
sponder for both RECIST 1.1 and Modiﬁed RECIST. A
RECIST 1.1 response was observed in two patients (20%
[95% CI: 0%–45%]). The durations of these responses
were 17.1 and 1.5 months. By Modiﬁed RECIST, 12
patients had pleural thickness measurements reported
at baseline. Seven patients had partial responses (three
unconﬁrmed), for an estimated response rate of 58%
(95% CI: 30%–86%). The median duration of these
responses was 5.6 months (95% CI: 1.5–17.1). The dis-
ease control rate was 92% (95% CI: 78%–100%) with
both criteria.In the 20-mg cohort, the median PFS by RECIST 1.1
was 13.6 months (95% CI: 8.0–18.6), the median PFS by
Modiﬁed RECIST was 8.6 months (95% CI: 6.9–13.1),
and the median OS was 13.6 months (95% CI: 12.0–26.8)
(see Fig. 1).
In total, 17 of 20 patients were evaluable for
response by RECIST 1.1. The RECIST 1.1 response rate
was 24% (95% CI: 3%–44%) and median PFS was 12.8
months (95% CI: 6.9–17.2). Nineteen patients were
evaluable by Modiﬁed RECIST, with a response rate of
63% (95% CI: 41%–85%), a median duration of
response of 5.6 months (95% CI: 3.0–9.7 months), and a
median PFS of 8.6 months (95% CI: 6.1–10.9). For all
patients, the disease control rate was 90% (95% CI:
Table 5. Efﬁcacy Summary from All Patients from the Phase I SWOG 0905
Cohorts
RECIST 1.1
RR
RECIST 1.1
Median PFS
Modiﬁed
RECIST RR
Modiﬁed RECIST
Median PFS DCRa Median OS
All patients n ¼ 17
24%
n ¼ 20
12.8 mo
n ¼ 19
63%
n ¼ 20
8.6 mo
n ¼ 20
90%
n ¼ 20
16.2 mo
30 mg of cediranib n ¼ 7
29%
n ¼ 7
12.8 mo
n ¼ 7
71%
n ¼ 7
10.1 mo
n ¼ 7
86%
n ¼ 7
16.2 mo
20 mg of cediranib n ¼ 10
20%
n ¼ 13
13.6 mo
n ¼ 12
58%
n ¼ 13
8.6 mo
n ¼ 13
92%
n ¼ 13
13.6 mo
aIdentical for both RECIST 1.1 and Modiﬁed RECIST.
RR, response rate; PFS, progression-free survival; DCR, disease control rate; OS, overall survival.
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CI: 10.5–28.7).
Discussion
The phase I portion of SWOG0905 established that
the MTD of cediranib was 20 mg daily in combination
with cisplatin-pemetrexed. This triplet regimen was
reasonably well tolerated with manageable toxicities.
The main grade 3 or 4 adverse events were gastroin-
testinal toxicity, dehydration, and hematologic disorders.
Cediranib certainly caused gastrointestinal toxicity and
dehydration, which are not typically seen with cisplatin-
pemetrexed alone.1 It is also suspected that cediranib0%
20%
40%
60%
80%
100%
0 12 24 36 48 60
Months After RegistrationPatients at Risk
20Modified RECIST 15 6 3 2 1 0 0 0 0 0
20RECIST 1.1 15 10 5 4 2 0 0 0 0 0
Modified RECIST
RECIST 1.1
N
20
20
Events
18
18
Median
in Months
8.6
12.8
95%
Conf. Int.
(6.1 - 10.9)
(6.9 - 17.2)
0%
20%
40%
60%
80%
100%
0 12 24 36 48 60
Months After Registration
20 17 13 8 7 5 5 1 1 1 0
Patients at Risk
All Patients
All Patients
N
20
Deaths
16
Median
in Months
16.2
95%
Conf. Int.
(10.5 - 28.7)
Figure 1. Progression-free and overall survival comparison in
the intent-to-treat population. RECIST, Response Evaluation
Criteria in Solid Tumors; Conf. Int., conﬁdence interval.had an additive effect on hematologic toxicity. There was
a 15% incidence of grade 3 or 4 thrombocytopenia with
the triplet regimen, which is higher than the 5.4% seen
in the Vogelzang trial1 with cisplatin-pemetrexed alone.
In the 30-mg cohort, grade 3 lymphopenia occurred in
two patients, but no cases were reported in the cediranib
20-mg cohort. The addition of cediranib did not appear
to increase the rates of grade 3 or 4 anemia or neu-
tropenia, which were 4.2% and 23.2%, respectively, in
the prior Vogelzang study.1
Although the enrollment in S0905 was small when
compared with the MAPS trial,2 the toxicity of the
current cisplatin-pemetrexed-cedirinib regimen appears
to be comparable to that of the cisplatin-pemetrexed-
bevacizumab regimen, for which a 71% grade 3 or 4
adverse event rate was reported. Cisplatin-pemetrexed-
cediranib caused less thromboembolism, hypertension,
and hemorrhage. The MAPS trial reported a 6% grade 3
thromboembolic rate, whereas there was only one grade
1 event in the S0905 trial. Grade 3 hypertension
occurred in 23% of patients with bevacizumab-cisplatin-
pemetrexed, compared with only one report with
cediranib-based therapy. Notably, there were no reports
of bleeding with cediranib-based therapy, whereas a
37.4% rate of hemorrhage (primarily grade 1 or 2
epistaxis) was reported for the bevacizumab-based
regimen.
Cediranib-cisplatin-pemetrexed did have higher rates
of proteinuria and gastrointestinal events compared
with the MAPS regimen. The bevacizumab-based
regimen reported a 16% rate of any grade proteinuria
(3.2% grade 3), whereas S0905 noted a 60% rate of
grade 1 or 2 proteinuria. The most common gastroin-
testinal side effect with cediranib was diarrhea.
Cediranib-induced diarrhea was manageable with
loperamide or lomotil; however, several patients needed
to take the antidiarrheal agents prophylactically. In
cohort 1, reducing the dose of cediranib to 20 mg daily
improved diarrhea. Unfortunately, there are currently
few data on the mechanism of action of VEGFR TKI–
induced diarrhea. Although these VEGFR TKIs are
cleared through the fecal pathway and the metabolites
August 2017 Cediranib, Cisplatin, and Pemetrexed in MPM 1307may cause colonic irritation, there are potential effects
from inhibition of intestinal microcirculation or even
off-target effects on gut motility that could also have a
signiﬁcant role in causing diarrhea.24
Although the sample size of the current study was
small and the patients were highly selected, there was a
signal of clinical beneﬁt with the addition of cediranib to
cisplatin-pemetrexed. The median PFS noted with
both the RECIST 1.1 and Modiﬁed RECIST criteria was
better than that reported for platinum-based doublets
(8.6 and 13.6 months versus 6.8 months).25 Of note, the
Vogelzang trial1 did not report PFS but had a time
to treatment failure of 5.7 months with cisplatin-
pemetrexed. In addition, the OS times were 13.6 and
16.2 months in the two S0905 cohorts compared with
12.1 months in the Vogelzang trial.1 This ﬁnding is
consistent with the results of the French Intergroupe
Francophone de Cancerologie Thoracique MAPs trial,2 in
which cisplatin-pemetrexed-bevacizumab had a median
PFS (9.2 months versus 7.3 months [hazard ratio ¼ 0.61,
p < 0.0001]) and OS (18.8 months versus 16.1 months
[hazard ratio ¼ 0.77, p ¼ 0.0167]) beneﬁt over platinum-
pemetrexed alone. Despite the control arm having
better outcomes than historical studies,1 the MAPs trial
clearly demonstrated survival beneﬁt with the addition
of bevacizumab to cisplatin-pemetrexed.
Whether inhibition of VEGF ligand alone by bev-
acizumab is sufﬁcient for survival beneﬁt or whether
targeting VEGFR along with PDGFR with cedirinib
provides greater synergistic beneﬁt remains to be seen.
Given that mesothelioma is known to be reliant on
the PDGF/PDGFR pathway for proliferation14–16 and
that prior studies with PDGFR inhibitors have shown a
clinical beneﬁt in mesothelioma,17 it is suspected that
multi-angiokinase inhibition may ultimately provide
additive beneﬁt. Cediranib has been studied in several
other tumor types with variable results. In NSCLC26 and
colorectal cancer27 the addition of cediranib to frontline
chemotherapy failed to improve survival, whereas phase
II and III trials in cervical28 and ovarian cancer29 have
demonstrated increased response rates and survival
outcomes.
For mesothelioma, the phase II portion of SWOG
0905, a randomized trial of cisplatin-pemetrexed with
and without cediranib, has completed enrollment and is
awaiting sufﬁcient events to be analyzed. Molecular
correlative studies in tumor tissue evaluating the VEGF/
VEGFR and PDGF/PDGFR pathway by immunohisto-
chemistry and plasma proﬁling through reverse phase
protein arrays are planned. A randomized phase II trial
of cisplatin-pemetrexed with and without nintedanib, an
oral TKI targeting VEGFR, PDGFR, and ﬁbroblast growth
factor receptor (FGFR), has completed accrual and is
now being expanded into a phase III randomized trial.Unlike cedirinib, nintedanib also targets FGFR, but
whether the FGFR pathway is a clinically relevant target
in mesothelioma remains unknown.30,31 Overall, there
is a growing body of literature indicating that anti-
angiogenic therapy in combination with chemotherapy
provides survival beneﬁt for patients with malignant
mesothelioma.
Conclusion
Cediranib in combination with cisplatin-pemetrexed
has a reasonable toxicity proﬁle and preliminary prom-
ising efﬁcacy. The randomized phase II portion of the
S0905 trial will evaluate the efﬁcacy of the triplet
regimen compared with the current standard therapy of
cisplatin-pemetrexed.
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